Screener
Olema Pharmaceuticals, Inc. OLMA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:10 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-218156
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (57,986) | (34,873) |
| Other income: | ||
| Interest income | 4,776 | 4,524 |
| Other income (loss) | 121 | (40) |
| Total other income | 4,897 | 4,484 |
| Net loss | $$(53,089) | (30,389) |
| Net loss per share, basic and diluted | $$(0.52) | (0.36) |
| Weighted average shares used to compute net loss per share, basic and diluted | 102,800,098 | 85,426,223 |
Item 1. Financial Statements.
FAQ
- What is Olema Pharmaceuticals, Inc.'s net income?
- Olema Pharmaceuticals, Inc. (OLMA) reported net income of -$53.09M in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s net income changed year-over-year?
- Olema Pharmaceuticals, Inc.'s net income decreased by 74.7% year-over-year, from -$30.39M to -$53.09M.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s net income has grown at a 22.9% compound annual growth rate (CAGR), from -$71.1M to -$162.45M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Olema Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude